ConductScience.org, home

Paper2351925

The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.

Olsson AG and 2 others. J Intern Med, 1990. Cited by 43 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. Papers, record 2351925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2351925

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
PubMed
Journal
J Intern Med
PubMed
Year
1990
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
43
iCite
Relative citation ratio, by iCite
1.57
iCite
Revised in PubMed
2019-09-03
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Olsson AGA G
2Ruhn GG
3Erikson UU

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ArteriosclerosisMajor topic
DietMajor topic
Femoral ArteryMajor topic
HyperlipidemiasMajor topic
LipidsMajor topic
NiacinMajor topic
Adult
Analysis of Variance
Blood Pressure
Cholesterol, VLDL
Combined Modality Therapy
Drug Evaluation
Humans
Hyperlipoproteinemias
Male
Middle Aged
Radiography
Smoking

Source PubMed

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.

PMIDTitleJournalYearIn PapersSource
11,122,726Niacin dosing: relationship to benefits and adverse effects.Curr Atheroscler Rep2000https://conductscience.org/library/papers/11122726PubMed
9,205,850Management of lipid disorders in the elderly.Drugs Aging1997https://conductscience.org/library/papers/9205850PubMed
8,920,175Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.Drugs Aging1996https://conductscience.org/library/papers/8920175PubMed
8,110,618Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality.Cardiovasc Drugs Ther1993https://conductscience.org/library/papers/8110618PubMed
8,043,977Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.Clin Investig1994https://conductscience.org/library/papers/8043977PubMed
1,576,071A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.Br J Clin Pharmacol1992https://conductscience.org/library/papers/1576071PubMed
1,390,323Cholesterol and coronary disease--outstanding questions.Cardiovasc Drugs Ther1992https://conductscience.org/library/papers/1390323PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2351925

GET https://conductscience.org/api/papers/v1/2351925/authors